XRTX

XORTX Therapeutics Inc. [XRTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

XRTX Stock Summary

Top 10 Correlated ETFs

XRTX

Top 10 Correlated Stocks

XRTX

In the News

XRTX Financial details

Company Rating
-
Market Cap
60.45M
Income
-7.78M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
10 Aug 2023
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.63
EPS next Y
-
EPS next Q
-
EPS this Y
300%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-21.18%
-
-
-
-
SMA20
-10.78%
SMA50
-4.21%
SMA100
-19.47%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.98-72.09
52W High
-98.77%
52W Low
-11.5%
RSI
41.4
Rel Volume
0.12
Avg Volume
50.53K
Volume
5.91K
Perf Week
-5.85%
Perf Month
-15.71%
Perf Quarter
-20.98%
Perf Half Y
-26.86%
-
-
-
-
Beta
0.18759
-
-
Volatility
0.01%, 0.06%
Prev Close
0.57%
Price
0.885
Change
1.33%

Something similar

Top by Market Cap
NVD.DE
APC.DE
VOO
ABEA.DE
MSF.DE
Top Correlated ETFs
TR7G.L
UBTS.L
UB74.L
U13G.L
TR3G.L
Top Correlated Stocks
9508.T
7241.T
9504.T
603286.SS
603819.SS
Similar Market Cap
ENGB.BR
OVB
SOTK
BDCO
SBX.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 50.53K
  • Market Capitalization 60.45M
  • Employee 3
  • CEO Dr. Allen Warren Davidoff Ph.D.
  • Headquarters Vancouver,BC,CA
  • IPO Date 2021-09-23
  • Website https://www.xortx.com

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.